Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medrad's 3T MRI-compatible infusion technology:

This article was originally published in Clinica

Executive Summary

Medrad has received US FDA 510(k) market clearance to expand the use of its magnetic resonance imaging (MRI)-compatible drug infusion system with scanners that have magnet strengths of up to, and including, 3T. Its Continuum technology was introduced in 2002 as the first MRI-compatible infusion system, meeting the need for safe and reliable infusion during MRI procedures in strengths up to 1.5T - the market standard at the time. With the advent of higher strength magnets, Medrad began extensive testing in 3T environments. MRI accessory equipment must meet safety standards and perform without interfering with the quality of medical images. "The clearance for 3T helps us reach new patients with this advanced technology," said Gary Bucciarelli, senior vice-president of the Indianola, Pennsylvania firm's magnetic resonance business unit.

You may also be interested in...



Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

EBITDA Margin Of 33% Not Sustainable, Krka Underlines

Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Topics

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel